Theravance Biopharma (TBPH) Return on Sales (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.02%, down 2.0% from the prior year.
• Return on Sales climbed to 0.0% in Q1 2026 per TBPH's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Sales peaked at 0.74% in Q3 2022 and troughed at 0.02% in Q4 2025.
• A 5-year average of 0.04% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales soared 73 bps in 2022, then plunged 75 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then slumped by 282 bps to 0.0% in 2023, then soared by 360 bps to 0.01% in 2024, then tumbled by 288 bps to 0.02% in 2025, then jumped by 88 bps to 0.0% in 2026.
• Business Quant data shows TBPH's Return on Sales at 0.0% in Q1 2026, 0.02% in Q4 2025, and 0.0% in Q3 2025.